

DAFTAR PUSTAKA

- Adli, F. K. (2021). Diabetes melitus gestasional: diagnosis dan faktor risiko. *Jurnal Medika Hutama*, 03(01), 1545–1551.
- Afrianti, R., Larucy, F., & Widayana, H. (2023). Interaksi obat anti tuberkulosis pada pasien tuberkulosis paru. *Jurnal Kesehatan Perintis*, 10(1), 53–59.
- Ahmad, J., Odin, J. A., Hayashi, P. H., Chalasani, N., Fontana, R. J., Barnhart, H., Cirulli, E. T., Kleiner, D. E., & Hoofnagle, J. H. (2017). Identification and characterization of fenofibrate-Induced liver injury. *Digestive Diseases and Sciences*, 62(12), 3596–3604. <https://doi.org/10.1007/s10620-017-4812-7>
- Al-Mrabeh, A. (2021). β -Cell dysfunction, hepatic lipid metabolism, and cardiovascular health in type 2 diabetes: new directions of research and novel therapeutic strategies. *Biomedicine*, 9(2), 1–26. <https://doi.org/10.3390/biomedicine9020226>
- Anggara, Y. R., Dermawan, A., Kurniati, I., & Nurhayati, D. (2019). Hasil pewarnaan basil tahan asam dengan penambahan carbol fuchsin dan pemanasan sputum sebelum dan sesudah pembuatan sediaan. *Jurnal Riset Kesehatan Poltekkes Depkes Bandung*, 11(1), 253–261.
- Auliafendri, N., Sinaga, A. H., & Gea, K. R. (2024). Interaksi obat antidiabetes dengan obat antituberkulosis (oat) pada pasien diabetes mellitus tipe 2 yang terinfeksi tb paru di instalasi rawat inap rumah sakit umum imelda pekerja indonesia medan. *JIFI (Jurnal Ilmiah Farmasi Imelda)*, 8(1), 1–9.
- Ayan, E., & DeMirici, H. (2022). A brief atlas of insulin. *Current Diabetes Reviews*, 19(6), 1–62. <https://doi.org/10.2174/1573399819666220610150342>
- Badawy, E., Abouelsaoud, K. A., Kabbash, A., & Ragab, A. (2023). Isoniazid, mechanism of action, biological activity, resistance and biotransformation. *Journal of Advanced Medical and Pharmaceutical Research*, 4(2), 42–46. <https://doi.org/10.21608/jampr.2023.202321.1052>
- Bailey, C. J. (2024). Metformin: therapeutic profile in the treatment of type 2 diabetes. *Diabetes, Obesity and Metabolism*, 26(S3), 3–19. <https://doi.org/10.1111/dom.15663>
- Baluku, J. B., Nalwanga, R., Kazibwe, A., Olum, R., Nuwagira, E., Mugenyi, N., Mulindwa, F., & Bongomin, F. (2024). Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in uganda. *Lipids*

in Health and Disease, 23(1), 1–9. <https://doi.org/10.1186/s12944-024-02063-7>

- Banday, M. Z. , Sameer, A. S. , & Nissar, S. (2020). Pathophysiology of diabetes: an overview. *Avicenna J Med*, 10(04), 174–188. https://doi.org/10.4103/ajm.ajm_53_20
- Baxter, K. (2010). *Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management* (Ninth Edition). Pharmaceutical Press.
- Bhat, Z. S., Rather, M. A., Maqbool, M., Lah, H. U. L., Yousuf, S. K., & Ahmad, Z. (2017). Cell wall: a versatile fountain of drug targets in mycobacterium tuberculosis. *Biomedicine and Pharmacotherapy*, 95, 1520–1534. <https://doi.org/10.1016/j.biopha.2017.09.036>
- Boadu, A. A., Yeboah-Manu, M., Osei-Wusu, S., & Yeboah-Manu, D. (2024). Tuberculosis and diabetes mellitus: the complexity of the comorbid interactions. *International Journal of Infectious Diseases*, 146, 1–8. <https://doi.org/10.1016/j.ijid.2024.107140>
- Bonavida, V., Frame, M., Nguyen, K. H., Rajurkar, S., & Venketaraman, V. (2022). Mycobacterium tuberculosis: implications of ageing on infection and maintaining protection in the elderly. *Vaccines*, 10(11). <https://doi.org/10.3390/vaccines10111892>
- Brake, J., Ajie, M., Sumpter, N. A., Koesoemadinata, R. C., Soetedjo, N. N. M., Santoso, P., Alisjahbana, B., Ruslami, R., Hill, P., & van Crevel, R. (2025). Inflammation and dyslipidaemia in combined diabetes and tuberculosis; a cohort study. *IScience*, 28(6), 1–15.
- Buasroung, P., Petnak, T., Liwtanakitpipat, P., & Kiertiburanakul, S. (2022). Prevalence of diabetes mellitus in patients with tuberculosis: a prospective cohort study. *International Journal of Infectious Diseases*, 116, 374–379. <https://doi.org/10.1016/j.ijid.2022.01.047>
- Caraux-Paz, P., Diamantis, S., de Wazières, B., & Gallien, S. (2021). Tuberculosis in the elderly. *Journal of Clinical Medicine*, 10(24), 1–13. <https://doi.org/10.3390/jcm10245888>
- Carrillo, A., & Gomez-Meade, C. (2020). Fasting glucose. In *Encyclopedia of Behavioral Medicine* (pp. 865–866). Springer.

- Chandrasekaran, P., Saravanan, N., Bethunaickan, R., & Tripathy, S. (2017). Malnutrition: modulator of immune responses in tuberculosis. *Frontiers in Immunology*, 8, 1–8. <https://doi.org/10.3389/fimmu.2017.01316>
- Chawla, S., Silva, F. T., Medeiros, S. A., Mekary, R. A., & Radenkovic, D. (2020). The effect of low-fat and low-carbohydrate diets on weight loss and lipid levels: a systematic review and meta-analysis. *Nutrients*, 12(12), 1–21. <https://doi.org/10.3390/nu12123774>
- Chisholm-Burns, M. A. , Schwinghammer, T. L. , Wells, B. G. , Malone, P. M. , Kolesar, J. M. , & DiPiro, J. T. (2016). *Pharmacotherapy principles & practice*. McGraw-Hill Education.
- da Silva, P. M., Duarte, S. J., von Hafe, P., Gil, V., Oliveira, J. N. D., & de Sousa, G. (2018). Standardization of laboratory lipid profile assessment: a call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines – executive summary: a consensus endorsed by the cardiovascular risk and prevention group of the portuguese internal medicine society, the portuguese atherosclerosis society, the portuguese society of cardiology, the portuguese society of laboratory medicine, and the portuguese association of clinical chemistry. *Revista Portuguesa de Cardiologia*, 37(4), 279–283. <https://doi.org/10.1016/j.repc.2017.07.013>
- Dawed, A. Y., Yee, S. W., Zhou, K., Leeuwen, N. van, Zhang, Y., Siddiqui, M. K., Etheridge, A., Innocenti, F., Xu, F., Li, J. H., Beulens, J. W., van der Heijden, A. A., Sliker, R. C., Chang, Y. C., Mercader, J. M., Kaur, V., Witte, J. S., Lee, M. T. M., Kamatani, Y., ... Pearson, E. R. (2021). Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas. *Diabetes Care*, 44(12), 2673–2682. <https://doi.org/10.2337/dc21-1152>
- de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: a consensus report by the american diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). *Diabetes Care*, 45(12), 3075–3090. <https://doi.org/10.2337/dci22-0027>
- Deng, L., Jia, L., Wu, X. L., & Cheng, M. (2025). Association between body mass index and glycemic control in type 2 diabetes mellitus: a cross-sectional study. *Diabetes, Metabolic Syndrome and Obesity*, 18, 555–563. <https://doi.org/10.2147/DMSO.S508365>
- Dixit, K., Kumar, K., & Singh, N. (2024). Combination of antidiabetic drugs and antilipidemic drugs for better clinical outcomes. *African Journal of Biological Sciences*, 6(14), 4326–4355. <https://doi.org/10.48047/AFJBS.6.14.2024.4326-4355>

- Djahido, M., Wiyono, W. I., & Mpila, D. A. (2020). Pola penggunaan insulin pada pasien diabetes melitus tipe 1 di instalasi rawat jalan rsup prof. dr. r. d kandou Manado. *Jurnal Ilmiah Farmasi*, 9(1), 82–89.
- Eljaaly, K. (2025). Drug Interactions with Rifampin in a tertiary hospital: a real-world cross-sectional study. *Saudi Journal of Clinical Pharmacy*, 4(3), 83–88. https://doi.org/10.4103/sjcp.sjcp_18_25
- Elshorbagy, A., Vallejo-Vaz, A. J., Barkas, F., Lyons, A. R. M., Stevens, C. A. T., Dharmayat, K. I., Catapano, A. L., Freiburger, T., Hovingh, G. K., Mata, P., Raal, F. J., Santos, R. D., Soran, H., Watts, G. F., Abifadel, M., Aguilar-Salinas, C. A., Alhabib, K. F., Alkhnifsawi, M., Almahmeed, W., ... Ray, K. K. (2025). Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH studies collaboration registry. *European Heart Journal*, 46(12), 1127–1140. <https://doi.org/10.1093/eurheartj/ehae791>
- Familianti, R. J., Sari, I., & Bastian. (2021). Perbedaan kadar trigliserida pada sampel darah segera disentrifugasi dan sampel darah dibekukan selama 20 menit sebelum disentrifugasi. *The Journal of Muhamadiyah Medical Laboratory Technologist*, 2(4), 120–126.
- Firdaus, M., Vebrian, G., & Pratiwi, A. (2021). Hubungan pengetahuan masyarakat terhadap kesiapsiagaan menghadapi covid-19 di masyarakat desa tanjakan rt.008/rw.003 rajeg kabupaten tangerang tahun 2021. *Nusantara Hasana Journal*, 1(7), 7–14.
- Fortuna, T. A., Rachmawati, H., Hasmono, D., & Karuniawati, H. (2022). Studi penggunaan obat anti tuberkulosis (OAT) tahap lanjutan pada pasien baru BTA positif. *Pharmacon: Jurnal Farmasi Indonesia*, 19(1), 62–71.
- Gabay, M., & Spencer, S. H. (2019). Drug interactions: scientific and clinical principles. *Am. Fam. Physician*, 99, 558–564.
- Galicía-García, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>
- Ganguly, R., Abraham, R. R., Prasad, R., & Rao, B. C. (2018). Hyperglycaemia induced by isoniazid preventive therapy. *Journal of Family Medicine and Primary Care*, 7(5), 1123–1125. https://doi.org/10.4103/jfmpe.jfmpe_197_18
- Gatete, G., Njunwa, K. J., Migambi, P., Ntaganira, J., & Ndagijimana, A. (2023). Prevalence and factors associated with sputum smear non-conversion after two months of tuberculosis treatment among smear-positive pulmonary

- tuberculosis patients in Rwanda: a cross-sectional study. *BMC Infectious Diseases*, 23(1), 1–10. <https://doi.org/10.1186/s12879-023-08395-6>
- Goddard, G., Rajagopal, S., Makhoul, G. W., & Raji, M. A. (2025). Metabolic syndrome in older adults: through the lens of institute for healthcare improvement's (IHI) 4Ms framework and social determinants of health. *Life*, 15(9), 1–3. <https://doi.org/10.3390/life15091370>
- Guarino, E., Nigi, L., Patti, A., Fondelli, C., & Dotta, F. (2012). Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. *Expert Opinion on Pharmacotherapy*, 13(9), 1377–1384.
- Hakim, L. N. (2020). Urgensi revisi undang-undang tentang kesejahteraan lanjut usia. *Aspirasi: Jurnal Masalah-Masalah Sosial*, 11(1), 43. <https://doi.org/10.22212/aspirasi.v11i1.1589>
- Halima, R. R., Rahimah, S. B., Saefulloh, A., Andriane, Y., & Suherian, E. (2019). Potensi interaksi obat antituberkulosis dan antidiabetes terhadap efek samping obat pada pasien tuberkulosis-diabetes melitus di rsudal-Ihsan bandung. *Jurnal Integrasi Kesehatan*, 1(1), 58–61. <http://ejournal.unisba.ac.id/index.php/jiks>
- Hardie, K. R., & Fenn, S. J. (2022). JMM profile: rifampicin: a broad-spectrum antibiotic. *Journal of Medical Microbiology*, 71(8), 001566. <https://doi.org/10.1099/jmm.0.001566>
- Harfiani, E., & Nurhakim, A. D. (2020). Faktor apa yang mempengaruhi rendahnya tingkat pengobatan tuberkulosis di lagoa jakarta. *Jurnal Ilmiah Kesehatan Masyarakat: Media Komunikasi Komunitas Kesehatan Masyarakat*, 12(3), 110–117.
- Hariyati, F., Hasmono, D., & Kasih, E. (2018). Profil penggunaan insulin pada pasien diabetes melitus tipe 2 dengan ulkus/gangren di rumah sakit umum daerah (RSUD) Kabupaten Sidoarjo. *Al of Pharmacy Science and Practice*, 5(1), 30–37.
- Hartiwan, M., & Fatwa, N. M. (2018). Kajian interaksi obat potensial antihipertensi pada pasien hipertensi rawat inap di rsud dr. soekardjo kota tasikmalaya periode april-mei 2017. *Jurnal Sains Dan Praktis*, 4(2), 20–25.
- Hartono, & Ediyono, S. ., (2024). Hubungan tingkat pendidikan, lama menderita sakit dengan tingkat pengetahuan 5 pilar penatalaksanaan diabetes mellitus di wilayah kerja puskesmas sungai durian Kabupaten KBU Raya Kalimantan Barat. *Journal of TSCS1Kep*, 9(1), 49–58.

- Hasan, R. (2021). Studi interaksi obat antihiperlipidemia pada pasien rawat jalan rsud dr. mm dunda limboto. *Jurnal Farmasi Tinctura*, 3(1), 15–24.
- Helmi, A., Veri, N., & Lina, L. (2024). Literature review: penanganan nonfarmakologi untuk penurunan kadar gula darah pada pasien diabetes mellitus. *Jurnal SAGO Gizi Dan Kesehatan*, 5(2), 547. <https://doi.org/10.30867/gikes.v5i2.1703>
- Hirota, T., Fujita, Y., & Ieiri, I. (2020). An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. *Expert Opinion on Drug Metabolism and Toxicology*, 16(9), 809–822. <https://doi.org/10.1080/17425255.2020.1801634>
- Joseph, J. (2025). Latent autoimmune diabetes in adults: diagnostic and therapeutic challenges. *Cureus*, 17, 1–5. <https://doi.org/10.7759/cureus.92356>
- Kementerian Kesehatan Republik Indonesia. (2011). *Pedoman interpretasi data klinik*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia. (2015). *Konsensus pengelolaan tuberkulosis dan diabetes melitus (tb-dm) di indonesia*. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Direktorat Pengendalian Penyakit Tidak Menular.
- Kementerian Kesehatan Republik Indonesia. (2019). *Keputusan menteri kesehatan republik indonesia nomor HL.01.07/MENKES/755/2019 tentang pedoman nasional pelayanan kedokteran tata laksana tuberkulosis*. Kementerian Kesehatan RI.
- Kementerian Kesehatan Republik Indonesia. (2020). *Pedoman nasional pelayanan kedokteran tata laksana tuberkulosis*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia. (2024). *Laporan program penanggulangan tuberkulosis tahun 2023*.
- Kementerian Kesehatan RI. (2020). *Petunjuk teknis penatalaksanaan tuberkulosis resistan obat di Indonesia*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI. (2023). *Petunjuk teknis pengobatan tuberkulosis monoresistan INH di Indonesia*. Kementerian Kesehatan RI.
- Kementerian Kesehatan RI. (2024). *Petunjuk teknis penatalaksanaan tuberkulosis resistan obat di Indonesia*. Kementerian Kesehatan Republik Indonesia.

- Khan, S. U., Khan, M. U., Riaz, H., Raggi, P., Valavoor, S., Khan, M. Z., Kołodziejczak, M., Khan, M. S., Krupica, T., Alkhouli, M., & Navarese, E. P. (2020). Meta-analysis of the relation of body mass index to cardiovascular outcomes in patients receiving intensive low-density lipoprotein cholesterol lowering therapy. *American Journal of Cardiology*, 125(5), 727–734. <https://doi.org/10.1016/j.amjcard.2019.12.006>
- Khatun, S., Afrin, S., & Alam, S. (2023). Molecular mechanism of clofazimine resistance in tuberculosis. *Journal of Infectious Diseases and Immunity*, 15(2), 41–52. <https://doi.org/10.5897/jidi2020.0199>
- Khoshnood, S., Goudarzi, M., Taki, E., Darbandi, A., Kouhsari, E., Heidary, M., Motahar, M., Moradi, M., & Bazyar, H. (2021). Bedaquiline: current status and future perspectives. *Journal of Global Antimicrobial Resistance*, 25, 48–59. <https://doi.org/10.1016/j.jgar.2021.02.017>
- Kim, J. H., Ahn, J. H., Kim, S. K., Lee, D. H., Kim, H. S., Shon, H. S., Jeon, H. J., Kim, T. H., Cho, Y. W., Kim, J. T., Han, S. M., Chung, C. H., Ryu, O. H., Lee, J. M., Lee, S. H., Kwon, M. J., Kim, T. K., Namgoong, I. S., Kim, E. S., ... Cha, B. Y. (2015). Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. *Journal of Diabetes Investigation*, 6(2), 219–226. <https://doi.org/10.1111/jdi.12261>
- Krishna, R. G., Boddu, S. L., Damera, S., Kadapa, A. K., Dharmareddy, K. M. R., & Katha, C. (2025). Advances in anti-tubercular agents: a comprehensive review. *Biomedical and Pharmacology Journal*, 18(1), 547–558. <https://doi.org/10.13005/bpj/3107>
- Krishna, S., & Jacob, J. J. (2021). *Diabetes mellitus and tuberculosis*.
- Krishnan, K. C., Mehrabian, M., & Lusi, A. J. (2018). Sex differences in metabolism and cardiometabolic disorders. *Current Opinion in Lipidology*, 29(5), 404–410. <https://doi.org/10.1097/MOL.0000000000000536>
- Kusuma, I. Y., Samodra, G., Komala, Y. I., Puspita, E., Apriliansa, J. P. A. P., & Faquina, A. A. (2022). Glucose lowering agent effect dapagliflozin adds on metformin therapy in mice. *Jurnal Ilmiah Farmako Bahari Ikhwan Yuda Kusuma*, 13(1). www.journal.uniga.ac.id
- Leonard, C. E., Han, X., Bilker, W. B., Flory, J. H., Brensinger, C. M., Flockhart, D. A., Gagne, J. J., Cardillo, S., & Hennessy, S. (2016). Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. *Diabetes Research and Clinical Practice*, 115, 60–67.

- Li, Y., Wang, F., Wu, L., Zhu, M., He, G., Chen, X., Sun, F., Liu, Q., Wang, X., & Zhang, W. (2019). Cycloserine for treatment of multidrug-resistant tuberculosis: A retrospective cohort study in China. *Infection and Drug Resistance*, 12, 721–731. <https://doi.org/10.2147/IDR.S195555>
- Lukito, J. , I. (2021). Antidiabetik oral kombinasi penghambat dpp-4 dan penghambat sglt-2. *Cermin Dunia Kedokteran*, 48(12), 397969.
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., Backer, D. G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richer, D. J., Sabatine, M. S., Taskinen, M. R., ... Wiklund, O. (2020). 2019ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European Heart Journal*, 32, 111–188. <https://doi.org/10.1093/eurheartj/ehz455>
- Maharani, M. W. , Yusmaini, H. , Karina, K. , & Harfiani, E. (2024). Hubungan pemberian obat antituberkulosis dengan kejadian efek sampingnya pada pasien tuberkulosis paru di RSUD sumedang tahun 2022. *Seminar Nasional Riset Kedokteran*, 5(1), 35–2.
- Maideen, N. M. P. (2018). Pharmacokinetic and pharmacodynamic Interactions of sulfonylurea antidiabetics. *European Journal of Medicine*, 6(2), 83–96. <https://doi.org/10.13187/ejm.2018.2.83>
- Malihah, D., & Emelia, R. (2022). Pola pengobatan antidiabetes terhadap pasien diabetes melitus tipe II rawat jalan di rsau dr. m. salamin. *Jurna Delima Harapan*, 9(1), 83–95.
- Mamonto, M., Sumampouw, J. E., & Walalangi, R. G. M. (2022). Kadar low density lipoprotein (ldl) dalam darah pada mahasiswa poltekkes Manado dengan kondisi obesitas. *Indonesian Journal of Medical Laboratory Technology*, 1(2), 51–56.
- Mar'iyah, K. , & Zulkarnain. (2021). Patofisiologi penyakit infeksi tuberkulosis. *Prosiding Seminar Nasional Biologi*, 7(1), 88–92. <http://journal.uin-alauddin.ac.id/index.php/psb>
- Marsanda, A., Kusumajaya, H., & Faizal, K. M. (2025). Faktor-faktor yang berhubungan dengan kejadian tuberkulosis paru BTA positif. *Jurnal Penelitian Keperawatan*, 1, 114–125.
- Marzel, R. (2021). Terapi pada dm tipe 1. *Jurnal Penelitian Perawat Profesional*, 3(1), 51–62. <http://jurnal.globalhealthsciencegroup.com/index.php/JPPP>

- May, M., & Schindler, C. (2016). Clinically and pharmacologically relevant interactions of antidiabetic drugs. *Therapeutic Advances in Endocrinology and Metabolism*, 7(2), 69–83. <https://doi.org/10.1177/2042018816638050>
- Meneses, M., Silva, B., Sousa, M., Sá, R., Oliveira, P., & Alves, M. (2015). Antidiabetic drugs: mechanisms of action and potential outcomes on cellular metabolism. *Current Pharmaceutical Design*, 21(25), 3606–3620. <https://doi.org/10.2174/1381612821666150710145753>
- Mito, A., Hirono, K., Ide, H., Ozawa, S., Ichida, F., & Taguchi, M. (2022). Effects of concomitant administration of pxx ligand drugs on the anticoagulant effects of warfarin. *Biological and Pharmaceutical Bulletin*, 45(6), 703–708. <https://doi.org/10.1248/bpb.b21-00853>
- Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., & Cohen, K. (2022). Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort. *Southern African Journal of HIV Medicine*, 23(1), 1. <https://doi.org/10.4102/sajhivmed.v23i1.1376>
- Moraes, E. G., Generoso, G., Bensenor, I. M., Santos, R. D., Santos, I. S., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., Toth, P. P., Lotufo, P. A., & Bittencourt, M. S. (2025). Association of obesity and LDL subfractions evaluated by body mass index, waist circumference, and diabetes status: the ELSA-Brasil study. *Diabetology and Metabolic Syndrome*, 17(1), 1–9. <https://doi.org/10.1186/s13098-025-01644-5>
- Moroz, M., & King, T. (2021). *Mycobacterium tuberculosis: pathogenesis and clinical findings: The Calgary Guide*. <https://calgaryguide.ucalgary.ca/mycobacterium-tuberculosis/>
- Nego, M. A., & Gayatri, A. (2023). Potensi interaksi obat tersering pada pasien sakit kritis. *Journal Of The Indonesian Medical Association*, 73(4).
- Neves, L. M. B., Silva, L. D. C., de Melo, M. T. B., Nobre, Y. V. S., Paulino, E. T., Ribeiro, Ê. A. N., Rodrigues, C. F. D. S., & Rodrigues, A. K. B. F. (2022). Drug interactions pharmacology: a narrative review. *American Journal of Pharmacology and Toxicology*, 17, 27–36. <https://doi.org/10.3844/ajptsp.2022.27.36>
- Nijland, H. M. J., Ruslami, R., Stalenhoef, J. E., Nelwan, E. J., Alisjahbana, B., Nelwan, R. H. H., Van Der Ven, A. J. A. M., Danusantoso, H., Aarnoutse, R. E., & Van Crevel, R. (2006). Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. *Clinical Infectious Diseases*, 43(7), 848–854.

- Ningrum, D. M., Ramdaniah, P., Permana, D. A. S., & Hariyadi, D. (2023). Studi potensi interaksi obat pasien covid-19 di rumah sakit umum daerah kota mataram. *Indonesian Journal Pharmacy and Natural Product*, 6(1), 24–29.
- Novrian, F., & Hajar, S. (2020). Perbandingan peningkatan kadar glukosa darah puasa sebelum dan sesudah pemberian madu hutan dan gula pasir mahasiswa angkatan 2015 fakultas kedokteran universitas muhammadiyah sumatera utara. *Jurnal Ilmiah Simantek*, 4(4), 146–152.
- Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018). Association between insulin resistance and the development of cardiovascular disease. *Cardiovascular Diabetology*, 17(1), 1–14. <https://doi.org/10.1186/s12933-018-0762-4>
- Pandey, S., Bajaj, S., & Goyal, V. V. (2023). Dyslipidemia in patients with tuberculosis and diabetes mellitus. *Journal of the Indian Medical Association*, 121(2), 41–43. <https://doi.org/10.1016/j.ebiom.2018.05.011>
- Patnaik, S., Pollevick, M. E., Lara-Breitinger, K. M., & Stone, N. J. (2022). Inter-individual variability in lipid response: a narrative review. *The American Journal of Medicine*, 135(12), 1427–1433.
- Paulina, A., Perangin Angin, M., & Hidayaturahmah, R. (2023). Evaluasi penggunaan obat kolesterol pada pasien hiperlipidemia di instalasi rawat jalan rumah sakit mutiara bunda. *Jurnal Farmasi Malahayati*, 6(1), 63–75.
- Perhimpunan Dokter Paru Indonesia. (2021). *Pedoman diagnosis dan penatalaksanaan di Indonseia* ((Edisi kedua)). Perhimpunan Dokter Paru Indonesia.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. (2022). *Panduan tata laksana dislipidemia 2022*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Perkumpulan Dokter Endokrinologi. (2021). *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia*. PB PERKENI.
- Perkumpulan Endokrinologi Indonesia. (2019). *Pedoman pengelolaan dislipidemia di Indonesia 2019* (Edisi pertama). PB PERKENI.
- Perkumpulan Endokrinologi Indonesia. (2021a). *Panduan pengelolaan dislipidemia di Indonesia 2021*. PB PERKENI.
- Perkumpulan Endokrinologi Indonesia. (2021b). *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021*. PB PERKENI.

- Pozzilli, P., & Pieralice, S. (2018). Latent autoimmune diabetes in adults: current status and new horizons. *Endocrinology and Metabolism*, 33(2), 147–159. <https://doi.org/10.3803/EnM.2018.33.2.147>
- Pradana, D. L. C., Rahmi, E. P., & Muti, A. F. (2021). Hypoglycemic effect of moringa oleifera aqueous extract in diabetic animal studies: a mechanisms review. *Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)*, 620–624. <https://doi.org/https://doi.org/10.2991/ahsr.k.210115.117>
- Pramudaningsih, I. N., Cahyanti, L., Yuliana, A. R., Fitriana, V., Khamdannah, E. N., & Fitriana, A. A. (2023). Pencegahan penularan tbc melalui implementasi cekoran bu titik (cegah resiko penularan melalui batuk efektif dan etika batuk) pada remaja di sman 2 Kudus. *Jurna Pengabdian Kesehatan*, 6(1), 77–87. <http://jpk.jurnal.stikescendekiautamakudus.ac.id>
- Prashant, Y., Asad, A., Ashish, G. K., Aditya, G. K., Somnath, B., Adesh, K., & Naresh, S. P. (2024). To assess the effect of dyslipidemia on treatment outcome of drug sensitive tb patients at a tertiary health care centre of north India. *African Journal of Biomedical Research*, 27(3s), 6049–6055. <https://doi.org/10.53555/AJBR.v27i3S.3382>
- Prawinda, Y. D., Ningrum, D. E. S., Mujirahayu, V., Noviana, D. W., Zuliyanti, E., Permatajaya, K. K. D., & Pranata, S. (2024). Penatalaksanaan lima pilar diabetes melitus oleh diabetisi: studi fenomenologi. *Journal Nursing Research Publication Media (NURSEPEDIA)*, 3(1), 12–25. <https://doi.org/10.55887/nrpm.v3i1.52>
- Preston, C. L. (2016). *Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance, and management* (Eleventh Edition). Pharmaceutical Press.
- Purba, S. K. R., & Manihuruk, F. N. M. (2023). Analisa Mycobacterium tuberculosis pada penderita diabetes melitus di rsud dr. r. m. djoelham Binjai. *HJP: Health Information Jurnal Penelitian*, 15, e784.
- Puspaseruni, K. (2021). Tatalaksana dislipidemia terkait penyakit kardiovaskular aterosklerosis (ascvd): fokus pada penurunan ldl-c. *Cermin Dunia Kedokteran*, 48(10), 395–401.
- Rahmasari, I., & Wahyuni, E. S. (2019). Efektivitas memordoca carantia (pare) terhadap penurunan kadar glukosa darah. *INFOKES*, 9(1), 57–64.
- Ramakrishnan, S. K., Russo, L., Ghanem, S. S., Patel, P. R., Oyarce, A. M., Heinrich, G., & Najjar, S. M. (2016). Fenofibrate decreases insulin clearance

and insulin secretion to maintain insulin sensitivity. *Journal of Biological Chemistry*, 291(46), 23915–23924. <https://doi.org/10.1074/jbc.M116.745778>

Ratnasari, P. M. D., Andayani, T. M., & Endarti, D. (2020). Analisis outcome klinis berdasarkan kualitas hidup dan biaya medik langsung pasien diabetes melitus tipe 2. *Jurnal Sains Farmasi & Klinis*, 7(1), 15–22.

Rizqiah, A., & Damayanti, A. (2022). Review interaksi obat-obat potensial terapi antibiotik pada infeksi saluran pernafasan pasien anak rawat inap di rumah sakit. *Journal of Pharmacy Science and Technology*, 3(2).

Rokhmah N. N., Gunawan, D. O., & Ningsih, W. (2025). Evaluasi penggunaan obat anti-tuberkulosis dan clinical outcome pasien tuberkulosis ekstra paru di rumah sakit paru dr. m goenawan partowidigdo. *Lambung Farmasi: Jurnal Ilmu Kefarmasian*, 6(1), 41–48.

Safitri, R. N., Hadi, W. S., & Astuti, T. D. (2024). Gambaran hemoglobin dan leukosit pasien tuberkulosis paru yang mendapat terapi obat antituberkulosis di rumah sakit x. *Jurnal Kesehatan Tambusai*, 5(4), 10841–10854.

Saito, K., Kagawa, T., Tsuji, K., Kumagai, Y., Sato, K., Sakisaka, S., Sakamoto, N., Aiso, M., Hirose, S., Mori, N., Tanaka, R., Uraoka, T., Takata, K., Ogawa, K., Mori, K., Sato, M., Nishiya, T., Takamatsu, K., Arakawa, N., ... Takikawa, H. (2020). Plasma lipid profiling of three types of drug-induced liver injury in japanese patients: a preliminary study. *Metabolites*, 10(9), 1–15. <https://doi.org/10.3390/metabo10090355>

Saltiel, A. R., & Olefsky, J. M. (2017). Inflammatory mechanisms linking obesity and metabolic disease. *Journal of Clinical Investigation*, 127(1), 1–4. <https://doi.org/10.1172/JCI92035>

Sarasmita, M. A., Amandari, I. G. A. A. E., Dewi, N. P. U. S., & Krisnayanti, M. W. (2019). SGLT-2 inhibitor: pilihan terapi baru untuk penderita diabetes melitus. *Jurnal Farmasi Udayana*, 8, 7–13. <https://doi.org/10.24843/jfu.2019.v08.i01.p02>

Sari, R. T., Handrianti, D., Agustina, A., Huzaifah, Z., & Saherna, J. (2022). Edukasi dan implementasi perawatan luka klien dengan diabetes melitus di kota banjarmasin. *Jurnal Kreativitas Pengabdian Kepada Masyarakat*, 5(10), 3250–3261. <https://doi.org/10.33024/jkpm.v5i10.6958>

Schelleman, H., Han, X., Brensinger, C. M., Quinney, S. K., Bilker, W. B., Flockhart, D. A., Li, L., & Hennessy, S. (2014). Pharmacoeconomic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with

fibrates and statins. *British Journal of Clinical Pharmacology*, 78(3), 639–648. <https://doi.org/10.1111/bcp.12353>

Schwinghammer T. L., Dipiro, J. T. , Ellingord, V. L. , & Dipiro, C. V. (2021). *Pharmacotherapy handbook eleventh edition* (Eleventh Edition). Mc Graw Hill.

Sheikh, B. A., Bhat, B. A., Mehraj, U., Mir, W., Hamadani, S., & Mir, M. A. (2020). Development of new therapeutics to meet the current challenge of drug resistant tuberculosis. *Current Pharmaceutical Biotechnology*, 22(4), 480–500. <https://doi.org/10.2174/1389201021666200628021702>

Shi, Z., & Han, S. (2025). Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins. *Heliyon*, 11(1), 1–23. <https://doi.org/10.1016/j.heliyon.2025.e41629>

Shrivastava, A., Kesavadev, J., Mohan, V., Saboo, B., Shrestha, D., Maheshwari, A., Makkar, B. M., Modi, K. D., & Kumar Das, A. (2023). Clinical evidence and practice-based guidelines on the utility of basal insulin combined oral therapy (metformin and glimepiride) in the current era. *Current Diabetes Reviews*, 19(8), 16–23. <https://doi.org/10.2174/1573399819666230109104300>

Simatupang, R. , & Kristina, M. (2023). Penyuluhan tentang diabetes melitus pada lansia penderita DM. *Jurnal Pengabdian Mandiri*, 2(3), 849–858. <http://bajangjournal.com/index.php/JPM>

Sinaga, T. M., Rusip, G., & Fachrial, E. (2024). *Studi interaksi obat antihiperlipidemia di rumah sakit umum royal prima medan*. 5(3), 7308–7314.

Singh, A., Chauhan, V., Kumar, C., Varma-Basil, M., & Prakash, A. (2025). An update on linezolid resistance in mycobacterium tuberculosis and the challenges ahead. *The Egyptian Journal of Chest Diseases and Tuberculosis*, 74(3), 267–273. https://doi.org/10.4103/ecdt.ecdt_81_24

Strikić, D., Vujević, A., Perica, D., Leskovic, D., Paponja, K., Pećin, I., & Merćep, I. (2023). Importance of dyslipidaemia treatment in individuals with type 2 diabetes mellitus a narrative review. *Diabetology*, 4(4), 538–552. <https://doi.org/10.3390/diabetology4040048>

Sugiyono. (2023). *Metode penelitian kuantitatif kualitatif dan r&d* (Edisi kedua). Penerbit Alfabeta.

Sultanpur, C. M., Satyanarayana, S., Reddy, N. S., Kumar, K. E., & Kumar, S. (2010). Drug-drug interaction between pravastatin and gemfibrozil

- (antihyperlipidemic) with gliclazide (antidiabetic) in rats. *Journal of Young Pharmacists*, 2(2), 152–155. <https://doi.org/10.4103/0975-1483.63157>
- Sun, L., Mi, K., Hou, Y., Hui, T., Zhang, L., Tao, Y., Liu, Z., & Huang, L. (2023). Pharmacokinetic and pharmacodynamic drug–drug interactions: research methods and applications. *Metabolites*, 13(8), 17. <https://doi.org/10.3390/metabo13080897>
- Suryaningrat, D. , & Fitrasari, E. (2021). Gambaran penggunaan obat dan biaya pengobatan penyakit tbc paru pasien BPJS rawat inap di RSUD Dokter Soedarso bulan september - november tahun 2018. *Jurnal Komunitas Farmasi Nasional*, 1(1).
- Taufiq, S. , & Noor, H. ,. (2019). Pathophysiology of dyslipidemia in modern medicine and its correlation in unani literature. *International Journal of Science and Healthcare Research*, 4(1), 362–364. www.ijshr.com
- te Brake, L. H. M., Yunivita, V., Livia, R., Soetedjo, N., van Ewijk-Beneken Kolmer, E., Koenderink, J. B., Burger, D. M., Santoso, P., van Crevel, R., Alisjahbana, B., Aarnoutse, R. E., & Ruslami, R. (2019). Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients. *Clinical Pharmacology and Therapeutics*, 105(3), 730–737. <https://doi.org/10.1002/cpt.1232>
- Udin, B., & Kholifah, E. (2021). Literature review: mekanisme kerja obat antidiislipidemia. *Jurnal Ilmiah Bakti Farmasi*, 6(1), 35–44.
- Unnissa, Z., Naseer, F., & Begum, M. (2023). Drug interaction. *International Journal of Pharmaceutical Sciences Review and Research*, 80(1), 29–40. <https://doi.org/10.47583/ijpsrr.2023.v80i01.006>
- van Stee, M. F., de Graaf, A. A., & Groen, A. K. (2018). Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. *Cardiovascular Diabetology*, 17(1), 1–22. <https://doi.org/10.1186/s12933-018-0738-4>
- Vrieling, F., Ronacher, K., Kleynhans, L., van den Akker, E., Walzl, G., Ottenhoff, T. H. M., & Joosten, S. A. (2018). Patients with concurrent tuberculosis and diabetes Have a pro-atherogenic plasma lipid profile. *EBioMedicine*, 32, 192–200. <https://doi.org/10.1016/j.ebiom.2018.05.011>
- Waller, D. G., & Hitchings, A. W. (2021). *Medical pharmacology and therapeutics e-book: medical pharmacology and therapeutics e-book*. Elsevier Health Sciences.

- Wang, K., Yang, A., Shi, M., Tam, C. C. H., Lau, E. S. H., Fan, B., Lim, C. K. P., Lee, H. M., Kong, A. P. S., Luk, A. O. Y., Tomlinson, B., Ma, R. C. W., Chan, J. C. N., & Chow, E. (2022). CYP2C19 loss-of-function polymorphisms are associated with reduced risk of sulfonylurea treatment failure in chinese patients with type 2 diabetes. *Clinical Pharmacology and Therapeutics*, *111*(2), 461–469. <https://doi.org/10.1002/cpt.2446>
- Wang, P., Pradhan, K., Zhong, X., & Ma, X. (2016). Isoniazid metabolism and hepatotoxicity. *Acta Pharmaceutica Sinica B*, *6*(5), 384–392. <https://doi.org/10.1016/j.apsb.2016.07.014>
- Widiasari, K. R., Made, I., Wijaya, K., & Suputra, P. A. (2021). Diabetes melitus tipe 2: faktor risiko, diagnosis, dan tatalaksana. *Ganesha Medicina Journal*, *1*, 114–120.
- Wollenhaupt, D., Wolters, J., Abd El Aziz, M., & Nauck, M. A. (2023). Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: A systematic analysis. *BMJ Open Diabetes Research and Care*, *11*(4), 1–11. <https://doi.org/10.1136/bmjdrc-2022-003296>
- World Health Organization. (2022). *WHO consolidated guidelines on tuberculosis module 4: treatment Ddug-susceptible tuberculosis treatment*. World Health Organization.
- World Health Organization. (2024). *Global tuberculosis report 2024*.
- Ye, Z., Li, L., Yang, L., Zhuang, L., Aspatwar, A., Wang, L., & Gong, W. (2024). Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective. *Exploration*, *4*(5), 1–31. <https://doi.org/10.1002/EXP.20230138>
- Yuan, Y. , Chen, W. , Luo, L. , & Chen, X. (2021). *Dyslipidemia: causes, symptoms and treatment*. *5*(2). <https://www.researchgate.net/publication/350153323>
- Zhou, L., Li, C., Gao, L., & Wang, A. (2015). High-density lipoprotein synthesis and metabolism (review). In *Molecular Medicine Reports* (Vol. 12, Issue 3, pp. 4015–4021). <https://doi.org/10.3892/mmr.2015.3930>
- Zhuang, X., Li, L., Liu, T., Zhang, R., Yang, P., Wang, X., & Dai, L. (2022). Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review. *Frontiers in Pharmacology*, *13*, 1–8. <https://doi.org/10.3389/fphar.2022.1037814>